- Home
- News and Resources
- Resources
- Wound Care Regulatory Roadmap: Navigating FDA Pathways with Confidence
Wound Care Regulatory Roadmap: Navigating FDA Pathways with Confidence
Bringing a wound care product to market requires more than innovation—it demands a clear, strategic regulatory plan. Whether you're developing a medical device, biologic, or combination product, understanding the right FDA pathway is critical to avoiding costly delays and ensuring compliance.
This roadmap outlines the key regulatory pathways—510(k), PMA, BLA, IND, IDE, and NDA—and provides actionable guidance to help you choose the right route for your product.
Regulatory Classifications: Know Your Review Center
Wound care products may fall under different FDA centers depending on their primary mode of action (PMOA):
- CDRH (Center for Devices and Radiological Health): Devices like dressings, NPWT systems, and wound imaging tools
- CDER (Center for Drug Evaluation and Research): Topical drugs, antimicrobials, and combination products with drug components
- CBER (Center for Biologics Evaluation and Research): Biologics such as cell-based therapies, skin substitutes, and tissue-engineered products
OCP Designation Process: Combination Product Strategy
If your product combines device, drug, or biologic elements, the Office of Combination Products (OCP) will determine the lead review center. This decision is based on the PMOA and can significantly impact your regulatory strategy and timeline.
Submission Types Explained
Submission Type | Best For | Key Requirements |
510(k) | Low- to moderate-risk devices | Substantial equivalence to predicate |
PMA | High-risk or novel devices | Clinical data, safety & effectiveness |
BLA | Biologic wound therapies | Purity, potency, safety, CMC data |
IND | Investigational biologics or drugs | Preclinical data, study protocol |
IDE | Investigational devices | Required for significant risk device trials |
NDA | New drug products | Full clinical and manufacturing data |
Case Examples
- 510(k): A hydrocolloid dressing with antimicrobial properties cleared based on a predicate dressing
- PMA: A novel NPWT system with integrated sensors requiring clinical validation
- BLA: A bioengineered skin substitute derived from neonatal fibroblasts
- Combination Product: A wound gel with both drug and device components reviewed under CDER with CDRH consultation
Strategic Tips for Regulatory Success
- Engage FDA early: Use pre-submission meetings to clarify expectations
- Plan for scalability: Align regulatory strategy with long-term product pipeline
- Document everything: Maintain detailed records of testing, manufacturing, and labeling
- Partner with experts: Regulatory consultants can help you avoid missteps and accelerate timelines